若年性脊椎関節炎における生物学的軽減と子供の転帰とフレア頻度の把握 (BACK-OFF JSpA)
若年性脊椎関節炎における生物学的軽減と子供の転帰とフレア頻度の把握 (バックオフ JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
調査の概要
状態
条件
詳細な説明
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Phoenix Children's
-
-
California
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
Palo Alto、California、アメリカ、94304
- Stanford University
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National Health System
-
-
Florida
-
Orlando、Florida、アメリカ、32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospital
-
St Louis、Missouri、アメリカ、63110
- St. Louis Children's Hospital
-
-
New York
-
New York、New York、アメリカ、10021
- Hospital for Special Surgery
-
Queens、New York、アメリカ、11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44302
- Akron Children's Hospital
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland、Oregon、アメリカ、97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- The Children's Hospital of Philadelphia
-
Pittsburgh、Pennsylvania、アメリカ、15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- UT Southwestern Medical Center
-
Houston、Texas、アメリカ、77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- Primary Children's Hospital
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1E8
- The Hospital for Sick Children
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
実験的:TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
実験的:TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
時間枠:12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
時間枠:12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 21-018442
- : GRT-00001036 (その他の助成金/資金番号:PCORI)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。